

Tablica 10. Prvih 30 lijekova po financijskoj potrošnji izraženo u kunama u 2022. godini, bolnička potrošnja

RBR	ATK	INN	UKUPNI IZNOS
1	L01XC18	pembrolizumab	370.484.052
2	L01EL01	ibrutinib	164.631.320
3	L01XC32	atezolizumab	126.417.667
4	L02BB04	enzalutamid	123.485.971
5	L01XC17	nivolumab	114.524.234
6	L04AA36	okrelizumab	107.194.637
7	L01XC07	bevacizumab	102.790.458
8	L01XC24	daratumumab	99.220.949
9	L04AX04	lenalidomid	91.285.334
10	L01XC13	pertuzumab	90.700.294
11	L01XC03	trastuzumab	85.870.985
12	B05AA01	albumin, ljudski	79.128.100
13	L01EF02	ribociklib	72.544.172
14	J06BA02	imunoglobulini, humani, za i.v. primjenu	71.453.567
15	L04AB02	infliksimab	70.531.016
16	L01XC14	trastuzumab emtanzin	60.411.342
17	B05BB01	elektroliti	59.330.658
18	L01XY02	pertuzumab, trastuzumab	58.187.390
19	L01XC02	rituksimab	48.493.192
20	L02BX03	abirateron	46.483.001
21	L01XX52	venetoklaks	45.620.512
22	L01EF01	palbociklib	45.541.254
23	L01CD01	paklitaksel	43.304.002
24	L03AA13	pegfilgrastim	42.692.790
25	L01EC02	dabrafenib	42.461.604
26	M09AX10	risdiplam	41.558.751
27	J01DH02	meropenem	38.772.372
28	S01XA27	voretigen neparvovek	38.343.702
29	L01EE01	trametinib	37.678.908
30	L01XC06	cetuksimab	37.454.751